PAVmed Inc.PAVMEarnings & Financial Report
PAVmed Inc. is a commercial-stage medical technology company that designs, develops and commercializes innovative diagnostic and therapeutic medical products. Its portfolio covers point-of-care diagnostics, interventional oncology and gastroenterology solutions, primarily serving healthcare providers and patients across the United States.
Revenue
$166.0K
Gross Profit
$-1.5M
Operating Profit
$-16.5M
Net Profit
$-14.5M
Gross Margin
-915.1%
Operating Margin
-9930.1%
Net Margin
-8757.2%
YoY Growth
N/A
EPS
$-2.10
PAVmed Inc. Q2 FY2023 Financial Summary
PAVmed Inc. reported revenue of $166.0K for Q2 FY2023, with a net profit of $-14.5M (up 43.0% YoY) (-8757.2% margin). Cost of goods sold was $1.7M, operating expenses totaled $15.0M.
Key Financial Metrics
| Total Revenue | $166.0K |
|---|---|
| Net Profit | $-14.5M |
| Gross Margin | -915.1% |
| Operating Margin | -9930.1% |
| Report Period | Q2 FY2023 |
PAVmed Inc. Annual Revenue by Year
PAVmed Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $2.5M).
| Year | Annual Revenue |
|---|---|
| 2023 | $2.5M |
PAVmed Inc. Quarterly Revenue & Net Profit History
PAVmed Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $996.0K | +25.9% | $64.4M | 6465.8% |
| Q2 FY2024 | $979.0K | +489.8% | $-10.8M | -1105.9% |
| Q1 FY2024 | $1.0M | +126.5% | $-15.2M | -1506.1% |
| Q4 FY2023 | $1.0M | +836.6% | $-14.0M | -1338.0% |
| Q3 FY2023 | $791.0K | +940.8% | $-17.7M | -2234.0% |
| Q2 FY2023 | $166.0K | — | $-14.5M | -8757.2% |
| Q1 FY2023 | $446.0K | +136.0% | $-17.9M | -4020.4% |
| Q2 FY2022 | $0 | — | $-25.5M | N/A |
Income Statement
| Q2 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $446000 | $166000 | $791000 | $1.0M | $1.0M | $979000 | $996000 |
| YoY Growth | N/A | 136.0% | N/A | 940.8% | 836.6% | 126.5% | 489.8% | 25.9% |
Balance Sheet
| Q2 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $82.5M | $65.3M | $53.7M | $42.0M | $33.1M | $37.3M | $39.4M | $30.6M |
| Liabilities | $41.0M | $54.5M | $54.5M | $57.8M | $57.1M | $57.8M | $58.1M | $39.9M |
| Equity | $22.0M | $-22.1M | $-31.5M | $-43.3M | $-53.8M | $-68.8M | $-73.9M | $-4.9M |
Cash Flow
| Q2 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.6M | $-16.4M | $-12.7M | $-11.1M | $-11.9M | $-13.1M | $-11.7M | $-8.9M |